Researchers evaluated three step-up therapies in 165 children (age range, 6–17 years) whose asthma was poorly controlled after 2 to 8 weeks of low-dose fluticasone therapy (100 µg twice daily).

Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. Log out ...

Novartis has moved a step closer to EU approval of its three-drug asthma therapy Enerzair Breezhaler, and now looks set to beat a rival therapy from GlaxoSmithKline to market. Enerzair (formerly ...